| Year |
Citation |
Score |
| 2021 |
Sharma SK, Suzuki M, Xu H, Korsen JA, Samuels Z, Guo H, Nemieboka B, Piersigilli A, Edwards KJ, Cheung NK, Lewis JS. Influence of Fc modifications and IgG subclass on biodistribution of humanized antibodies targeting L1CAM. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 34353869 DOI: 10.2967/jnumed.121.262383 |
0.428 |
|
| 2020 |
Nemieboka B, Sharma SK, Rao TD, Edwards KJ, Yan S, Wang P, Ragupathi A, Piersigilli A, Spriggs DR, Lewis JS. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation. Nuclear Medicine and Biology. 86: 9-19. PMID 32403071 DOI: 10.1016/J.Nucmedbio.2020.04.006 |
0.479 |
|
| 2018 |
Suzuki M, Xu H, Guo H, Nemieboka B, Wu Z, Lewis J, Cheung NV. Abstract A30: Novel T-cell engaging antibodies against L1CAM for neuroblastoma Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-A30 |
0.334 |
|
| 2017 |
Rao TD, Fernández-Tejada A, Axelrod A, Rosales N, Yan X, Thapi S, Wang A, Park KJ, Nemieboka B, Xiang J, Lewis JS, Olvera N, Levine DA, Danishefsky SJ, Spriggs D. Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. Acs Chemical Biology. PMID 28617578 DOI: 10.1021/Acschembio.7B00305 |
0.428 |
|
| 2016 |
Sharma SK, Nemieboka B, Sala E, Lewis JS, Zeglis BM. Molecular Imaging of Ovarian Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27127223 DOI: 10.2967/Jnumed.115.172023 |
0.466 |
|
| Show low-probability matches. |